Morus Alba leaf extract affects metabolic profiles, biomarkers inflammation and oxidative stress in patients with type 2 diabetes mellitus: A double-blind clinical trial.
- 2022-06
- Clinical nutrition ESPEN 49
- Mohsen Taghizadeh
- Azam Mohammad Zadeh
- Zatollah Asemi
- Amir Hosein Farrokhnezhad
- Mohammad Reza Memarzadeh
- Zarin Banikazemi
- Mohammad Shariat
- Rana Shafabakhsh
- PubMed: 35623877
- DOI: 10.1016/j.clnesp.2022.03.027
Study Design
- Type
- Randomized Controlled Trial (RCT)
- Sample size
- n = 60
- Population
- 60 patients with T2DM
- Methods
- randomized, double-blind, placebo-controlled trial, Morus Alba extract (300 mg) or placebo twice a day
- Blinding
- Double-blind
- Duration
- 12 weeks
- Funding
- Unclear
Introduction
Morus Alba extract, despite its special properties, has been less studied in terms of its effects on metabolic profiles in patients with type 2 diabetes mellitus (T2DM). This study was carried out to determine the effects of Morus Alba extract, known as white mulberry, on liver enzymes, biomarkers of inflammation and oxidative stress, insulin metabolism and lipid profiles in patients with T2DM.Methods
The current randomized, double-blind, placebo-controlled trial was conducted among 60 patients with T2DM. Subjects were randomly divided into 2 groups to receive either Morus Alba extract (300 mg) (n = 30) or placebo (n = 30) twice a day. Fasting blood samples were collected at the baseline and 12 weeks after intervention to quantify related markers.Results
Morus Alba extract intake significantly decreased insulin (P = 0.026) and malondialdehyde (MDA) (P < 0.001), and significantly increased HDL-cholesterol concentrations (P = 0.001) compared with the placebo. However, Morus Alba extract intake did not affect other metabolic profiles.Conclusions
The results of this study shown that the 12-week administration of Morus Alba extract among subjects with T2DM had beneficial effects on HDL-cholesterol, insulin and MDA levels, but did not affect other metabolic profiles. The present study was registered in the Iranian website for clinical trials as http://www.irct.ir: IRCT2016081312438N21.Research Insights
Morus Alba extract intake significantly decreased insulin (P = 0.026) and malondialdehyde (MDA) (P < 0.001), and significantly increased HDL-cholesterol concentrations (P = 0.001) compared with the placebo.
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 300 mg twice a day
Morus Alba extract intake did not affect other metabolic profiles.
- Effect
- Neutral
- Effect size
- Small
- Dose
- 300 mg twice a day
Morus Alba extract intake significantly decreased insulin (P = 0.026) and malondialdehyde (MDA) (P < 0.001), and significantly increased HDL-cholesterol concentrations (P = 0.001) compared with the placebo.
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 300 mg twice a day
Morus Alba extract intake did not affect other metabolic profiles.
- Effect
- Neutral
- Effect size
- Small
- Dose
- 300 mg twice a day
Morus Alba extract intake did not affect other metabolic profiles.
- Effect
- Neutral
- Effect size
- Small
- Dose
- 300 mg twice a day
Morus Alba extract intake did not affect other metabolic profiles.
- Effect
- Neutral
- Effect size
- Small
- Dose
- 300 mg twice a day
Morus Alba extract intake significantly decreased insulin (P = 0.026) and malondialdehyde (MDA) (P < 0.001), and significantly increased HDL-cholesterol concentrations (P = 0.001) compared with the placebo.
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 300 mg twice a day
Morus Alba extract intake did not affect other metabolic profiles.
- Effect
- Neutral
- Effect size
- Small
- Dose
- 300 mg twice a day
Morus Alba extract intake did not affect other metabolic profiles.
- Effect
- Neutral
- Effect size
- Small
- Dose
- 300 mg twice a day
Morus Alba extract intake did not affect other metabolic profiles.
- Effect
- Neutral
- Effect size
- Small
- Dose
- 300 mg twice a day